Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02781610 · ClinicalTrials.gov registry record · Phase 4
Standardized Treatment of Pulmonary Exacerbations II
A Phase 4 study, sponsored by Chris Goss.
- Completed
- Registry status
- Phase 4
- Development phase
- 982
- Enrollment target
NCT02781610 is a Phase 4 study that has completed, run by Chris Goss. The registered enrollment target is 982 participants.
The verdict
NCT02781610, a Phase 4 study, has completed, sponsored by Chris Goss.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 982 participants
- Enrollment target
Study Summary
Cystic fibrosis (CF), a life-shortening genetic disease, is marked by acute episodes during which symptoms of lung infection increase and lung function decreases. These pulmonary exacerbations are treated with varying antibiotics for varying time periods based on needs determined by individual patients, their families, and the health care providers. Cystic fibrosis pulmonary guidelines for the treatment of pulmonary exacerbation published by the Cystic Fibrosis Foundation (CFF) in 2009 provided recommendations for treatment and also identified key questions for which additional studies were needed. A strong desire among clinicians to reduce treatment durations (and reduce cost, inconvenience, and potential toxicities) is in conflict with belief that patients not responding robustly to treatment might benefit from extending treatment. This randomized, controlled, open-label study is designed to evaluate the efficacy and safety of differing durations of IV treatment, given in the hospital or at home for a pulmonary exacerbation in adult patients with CF.
Interventions
- DRUG Standard of care IV antibiotic(s)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 982 participants |
| Start Date | 2016-06 |
| Est. Completion | 2020-03-06 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02781610
The ClinicalTrials.gov registry entry for NCT02781610 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 982 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Chris Goss, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Standard of care IV antibiotic(s) is the first listed.
NCT02781610 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02781610 about?
NCT02781610 is a clinical study titled "Standardized Treatment of Pulmonary Exacerbations II". Cystic fibrosis (CF), a life-shortening genetic disease, is marked by acute episodes during which symptoms of lung infection increase and lung function decreases. These pulmonary exacerbations are treated with varying antibiotics for varying time periods based on needs determined by individual patie...
What is the current status of trial NCT02781610?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 982 participants. The study started on 2016-06. Estimated completion is 2020-03-06.
What interventions are being tested in trial NCT02781610?
The interventions under investigation include: Standard of care IV antibiotic(s) (DRUG).
Who is sponsoring clinical trial NCT02781610?
This trial is sponsored by Chris Goss, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.